Short answer: As of the JPML report dated November 2, 2026, 4,082 lawsuits are pending in MDL 3094 (stomach and bowel injuries) and 278 in MDL 3163 (NAION vision loss). Both are before Judge Karen S. Marston in the Eastern District of Pennsylvania. No settlement has been announced and no bellwether trial date is set.
The court has taken the science first. On August 15, 2025 it ruled that a gastroparesis claim needs a gastric emptying study to support the diagnosis. The court then held a Rule 702 (expert evidence) hearing on Cross Cutting Issues 2 and 3, warning adequacy and preemption, in September 2026. Closing arguments on those motions were heard on October 13, 2026. No ruling is posted on the court page as of November 13, 2026, and Judge Marston continues to hold monthly status conferences.
- Drugs covered: Ozempic, Wegovy, Rybelsus, Victoza and Saxenda (Novo Nordisk); Trulicity, Mounjaro and Zepbound (Eli Lilly).
- Main injuries: gastroparesis, ileus or intestinal blockage, gallbladder injury and severe vomiting; NAION vision loss in the second MDL.
- What to watch: the Rule 702 ruling, which will shape which claims move forward.
Read the full Ozempic lawsuit guide or request a free, confidential case review.
SourcesJPML report2 Nov 2026MDL 3094 court pageE.D. Pa.Rule 702 opinionE.D. Pa., 15 Aug 2025


